WHO ICTRP trial
Suppression of Prostate cancer by Naftopidil
JPRN-jRCTs031180176 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031180176 |
|---|---|
| Public title | Suppression of Prostate cancer by Naftopidil |
| Scientific title | A prospective randomized controlled study on Suppression of Prostate cancer by Naftopidil - SNAP study |
| Primary sponsor | Yamada Daisuke |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Conditions | Prostate Cancer |
| Interventions | Naftopidil is administered to the patient assigned to naftopidil administration group (3-5 years). Not to those assigned to non-administration group (3-5 years). The initial dose (2 weeks or more) should be 25 mg daily, and thereafter it… |
| Registration date | May 3, 2019 |
| Target size | 1200 |
| Secondary IDs | UMIN000022862 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: